TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$244 Million

PMV Pharmaceuticals

Initial Public Offering

Bookrunner, September 2020

PMV Pharmaceuticals

PMV Pharmaceuticals, Inc. is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations. The Company’s lead product candidate, PC14586, is designed to potently and selectively correct p53 misfolding caused by a specific p53 mutation, Y220C, while sparing wild-type p53. In addition, the Company is leveraging its precision oncology platform to develop a pipeline of oral small molecule product candidates that structurally correct other p53 hotspot mutations to restore their wildtype function.